News

New analyses and extended follow-up from the BRIGHT study demonstrated that bivalirudin remained superior to both heparin monotherapy and heparin plus tirofiban for patients with acute myocardial...

September 22, 2014 — A first-of-its kind study found that using a cerebral protection device during transcatheter aortic valve replacement (TAVR) can significantly reduce the number and volume of...

September 22, 2014 — According to a new study, while it is common for patients who have migraine to have a patent foramen ovale, a procedure to repair this heart defect does not significantly...

VADs Gain Popularity Artificial Hearts Remain Ideal GlobalData

Robert Littlefield, MSc, GlobalData's senior analyst covering Medical Devices, said: “Since the first implantation of the Jarvik 7 in 1982, artificial heart devices have evolved significantly...

According to a new study, patients receiving six months of dual antiplatelet therapy (DAPT) after receiving a second-generation drug-eluting stent (DES) appeared to have similar outcomes to...

U.S. CoreValve High Risk trial TCT 2014

According to a new study, transcatheter aortic valve replacement (TAVR) provided meaningful clinical benefits relative to surgical aortic valve replacement (SAVR) in high risk patients with...

Study Blood Thinner Heart Attack Patients

The largest prospective longitudinal study of acute myocardial infarction (MI) patients offers unique insight into the use, safety and effectiveness of blood thinners prasugrel and clopidogrel in...

September 19, 2014 — A new study investigating different durations of triple therapy for anticoagulation after drug-eluting stent (DES) implantation demonstrated that six weeks of drug therapy was...

September 19, 2014 — According to a new study, peritoneal hypothermia is feasible for patients who have suffered ST-segment elevation myocardial infarction (STEMI). However, the procedure was...

PARTNER I Trial TCT 2014 TAVR Heart Valve Repair

New data from a landmark clinical trial found that after five years, transcatheter aortic valve replacement (TAVR) demonstrated a persistent mortality benefit, improved functional status, and...

A new study found that fractional flow reserve (FFR)-guided provisional side branch (SB) stenting of true coronary bifurcation lesions yields similar outcomes to the current standard of care. The...

September 17, 2014 — A new clinical trial found that vascular closure devices (VCDs) are non-inferior to manual compression in patients undergoing transfemoral coronary angiography. The findings...

September 17, 2014 — GE Healthcare announced it has installed its Cath Lab Efficiency Manager at Saint Luke’s Mid America Heart Institute in Kansas City, Mo. The solution is a new analytical tool...

September 16, 2014 — A quarter of adults in the United States have two or more chronic medical conditions, as do more than two-thirds of seniors, yet there are few clinical practice guidelines for...

September 15, 2014 — A new minimally invasive surgery involving a stent graft made from a 3-D image of the patient’s anatomy could eliminate the need for open surgery for some patients suffering...

PressureWire St. Jude Medical Two-year FAME 2 Data FFR-guided PCI

St. Jude Medical Inc. announced primary outcome two-year data from the FAME 2 Trial, which demonstrated sustained superiority with FFR-guided PCI using St. Jude Medical PressureWire technology in...

September 12, 2014 — Volcano Corp. announced it will be launching its interventional precision guidance tools at the 27th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific...

September 11, 2014 — Medtronic announced the U.S. Food and Drug Administration (FDA) 510(k) clearance and launch of the NC Euphora noncompliant balloon dilatation catheter. The new device will be...

U.S.-based Medtronic said it would purchase Ireland-based Covidien for $42.9 billion, combining two of the world's biggest medical device makers and helping Medtronic savings with a headquarters...

Transcatheter Cardiovascular Therapeutics (TCT) has announced the late-breaking trial presentations at TCT 2014, Sept. 13-17.